IFRX N Stock Overview
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
InflaRx N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.00 |
| 52 Week High | US$27.00 |
| 52 Week Low | US$27.00 |
| Beta | 1.25 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -95.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| IFRX N | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how IFRX N performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how IFRX N performed against the MX Market.
Price Volatility
| IFRX N volatility | |
|---|---|
| IFRX N Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: IFRX N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IFRX N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 62 | Niels Riedemann | www.inflarx.de |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
InflaRx N.V. Fundamentals Summary
| IFRX N fundamental statistics | |
|---|---|
| Market cap | Mex$1.35b |
| Earnings (TTM) | -Mex$786.98m |
| Revenue (TTM) | Mex$1.16m |
1,157x
P/S Ratio-1.7x
P/E RatioIs IFRX N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IFRX N income statement (TTM) | |
|---|---|
| Revenue | €63.09k |
| Cost of Revenue | €532.26k |
| Gross Profit | -€469.17k |
| Other Expenses | €42.20m |
| Earnings | -€42.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | -743.67% |
| Net Profit Margin | -67,630.69% |
| Debt/Equity Ratio | 0% |
How did IFRX N perform over the long term?
See historical performance and comparison